Main Menu
Menu

Steve Brachmann

Publish Date
News
C4IP Urges USTR to Use USMCA Joint Review to Address Shortcomings on IP Protections
IPWatchdog
Steve Brachmann
Resources
Public Comments
C4IP Comments RE: India’s Invitation to Comment on Its Drug Approval Regime
Council for Innovation Promotion
Resources
Public Comments
C4IP Comments RE: Operation of the Agreement between the United States of America, the United Mexican States, and Canada (USTR-2025-0004)
Council for Innovation Promotion
Blog
Why Continued Innovation Matters: Keytruda and the “Product Hopping” Myth

The FDA recently approved a new version of Keytruda, a cancer immunotherapy medicine that is one of the world’s most successful drugs....

Council for Innovation Promotion
BlogFact Checks
Fact Check: The Myth of So-Called “Royalty Free” and “Open” Standards

The word “open” has become increasingly misused in the world of technology standards. In policy and antitrust terms, an open standard is...

Council for Innovation Promotion
Blog
Highlights from the October 8 PERA Hearing

On October 8, the Senate Judiciary Subcommittee on Intellectual Property held a hearing on the Patent Eligibility Restoration Act (PERA) to examine...

Council for Innovation Promotion
News
Commerce Moves to Take Cut of Research Patents
American Institute of Physics
Clare Zhang
News
Counting Patents, Not Progress: Another Misdiagnosis by I-MAK
IPWatchdog
Mary Till and Rachael Dippold
C4IPResources
Letters
C4IP Letter to Senate and House IP Subcommittees RE: Designating October as National IP Month
Council for Innovation Promotion
Press Releases
Council for Innovation Promotion Urges Caution Regarding I-MAK’s New Report on Patents and Drug Pricing

WASHINGTON (October 20, 2025) — Today, the Council for Innovation Promotion (C4IP) Executive Director Frank Cullen released the following statement regarding a...

Council for Innovation Promotion
Blog
Inventor Spotlight: Malcom McLean

C4IP is honoring Malcom McLean (1913-2001), whose invention of containerized shipping revolutionized global trade. Born into a farming family in North Carolina,...

Council for Innovation Promotion
Op-Eds
Congress should base patent policy on evidence, not accusations
Lawmakers must reject I-MAK’s questionable data and abandon two damaging bills, the Drug Competition Enhancement Act and Affordable Prescriptions for Patients Act....
IAM
Frank Cullen
News:

News:

C4IP Urges USTR to Use USMCA Joint Review to Address Shortcomings on IP Protections,

11/07/2025
Resources:

Resources:

C4IP Comments RE: India’s Invitation to Comment on Its Drug Approval Regime,

11/06/2025
Resources:

Resources:

C4IP Comments RE: Operation of the Agreement between the United States of America, the United Mexican States, and Canada (USTR-2025-0004),

11/03/2025
Blog:

Blog:

Why Continued Innovation Matters: Keytruda and the “Product Hopping” Myth,

11/03/2025
Blog:

Blog, Fact Checks:

Fact Check: The Myth of So-Called “Royalty Free” and “Open” Standards,

10/30/2025
Blog:

Blog:

Highlights from the October 8 PERA Hearing,

10/24/2025
News:

News:

Commerce Moves to Take Cut of Research Patents,

10/21/2025
News:

News:

Counting Patents, Not Progress: Another Misdiagnosis by I-MAK,

10/21/2025
C4IP:

C4IP, Resources:

C4IP Letter to Senate and House IP Subcommittees RE: Designating October as National IP Month,

10/21/2025
Press Releases:

Press Releases:

Council for Innovation Promotion Urges Caution Regarding I-MAK’s New Report on Patents and Drug Pricing,

10/20/2025
Blog:

Blog:

Inventor Spotlight: Malcom McLean,

10/17/2025
Op-Eds:

Op-Eds:

Congress should base patent policy on evidence, not accusations,

10/11/2025
Scroll to Top